Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 597-601

  D’Amato, Robert J ^a   Lentzsch, Suzanne ^a   Anderson, Kenneth C ^a   Rogers, Michael S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOTHALIDOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

EID: 0035211277     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90031-4     Document Type: Article

References (47)

1. Tumor angiogenesis: Therapeutic implications
2. Tumor growth and neovascularization: An experimental model using the rabbit cornea
3. A model of angiogenesis in the mouse cornea
4. Tumor angiogenesis
5. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
6. Thalidomide is an inhibitor of angiogenesis
7. Thalidomide and congenital abnormalities
8. A short history of thalidomide embryopathy
9. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
10. Teratogenic effect of N-phthalyl-DL-glutamic acid following intraperitoneal application in mice
11. Effects of thalidomide treatment of inbred female mice on pregnancy, fetal development, and mortality of offspring
12. Effects of maternal thalidomide treatment on pregnancy, fetal development, and mortality of the offspring in random-bred mice
13. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
14. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
15. Phase II evaluation of thalidomide in patients with metastatic breast cancer
16. Continuous low dose thalidomide: A phase lI study in advanced melanoma, renal cell, ovarian and breast cancer
17. Development of angiogenesis inhibition as therapy for prostate cancer
18. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches
19. New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide
20. Irinotecan and thalidomide in metastatic colorectal cancer
21. Bone marrow angiogenesis and progression in multiple myeloma
22. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44
23. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies
24. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
25. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
26. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
27. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A
28. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells
29. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma
30. Effects of phosphodiesterase inhibitors on cytokine production by microglia
31. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: Implications for their mode of action in rheumatoid arthritis
32. IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis
33. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
34. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity
35. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity
36. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production
37. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
38. Inhibition of angiogenesis in vivo by interleukin 12
39. Interferongamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
40. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10
41. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb
42. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion
43. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans
44. Thalidomideinduced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
45. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood
46. Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide
47. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha